ClinicalTrials.gg
CompletedNCT05567029Updated Apr 28, 2023

Study to Evaluate the Relative Bioavailability of Two Risankizumab Drug Product Presentations in Healthy Volunteers.

A Phase 1 interventional study of Risankizumab Dose A and Risankizumab Dose B in Healthy Volunteers, sponsored by AbbVie. Completed at 5 sites in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-28.

Sponsored by AbbVie · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Apr 2023, 3 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
198
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This study will assess how safe risankizumab is and how risankizumab moves through the body of adult healthy participants. Adverse Events will be assessed.

Risankizumab is an investigational drug being developed for the treatment of Crohn's Disease. Participants are randomly assigned to one of the 2 treatment groups. Approximately 198 adult healthy volunteers will be enrolled in at least 4 sites across the world.

All participants will receive risankizumab as subcutaneous injections in one of the 2 different formulations.

There may be higher burden for participants in this trial. Participants will be confined for 10 days and followed up for 140 days. Adverse Events and blood tests will be collected.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Risankizumab
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight greater than 40 kg and less than 100 kg at screening and upon initial confinement.

Exclusion criteria

Exclusion Criteria:

  • Previous exposure to any anti-interleukin-12/23 or anti-interleukin-23 treatment.
  • Intention to perform strenuous exercise to which the participant is unaccustomed within one week prior to administration of study drug or during the study.
05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
198 participants (actual)

Study arms

  • Experimental
    Risankizumab Dose A

    Participants will receive subcutaneous dose of risankizumab dose A.

    Drug: Risankizumab Dose A

  • Experimental
    Risankizumab Dose B

    Participants will receive subcutaneous dose of risankizumab dose B.

    Drug: Risankizumab Dose B

Interventions

  • DrugRisankizumab Dose A

    Prefilled Syringe

  • DrugRisankizumab Dose B

    Prefilled Syringe

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    Maximum Observed Plasma Concentration (Cmax)

    Time frame: Approximately up to 113 days

  2. Time to Maximum Observed Plasma Concentration (Tmax)

    Time to Maximum Observed Plasma Concentration (Tmax)

    Time frame: Approximately up to 113 days

  3. Apparent Terminal Phase Elimination Rate Constant (β)

    Apparent Terminal Phase Elimination Rate Constant (β)

    Time frame: Approximately up to 113 days

  4. The Terminal Phase Elimination Half-Life (t1/2)

    The Terminal Phase Elimination Half-Life (t1/2)

    Time frame: Approximately up to 113 days

  5. The Area Under the Plasma Concentration-Time Curve (AUC) from Time 0 to Time of the Last Measurable Concentration (AUCt)

    The Area Under the Plasma Concentration-Time Curve (AUC) from Time 0 to Time of the Last Measurable Concentration (AUCt)

    Time frame: Approximately up to 113 days

  6. The Area Under the Plasma Concentration-Time Curve (AUC) from Time 0 to Infinity (AUC∞)

    The Area Under the Plasma Concentration-Time Curve (AUC) from Time 0 to Infinity (AUC∞)

    Time frame: Approximately up to 113 days

  7. Number of Participants with Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.

    Time frame: Approximately up to 140 days

07

Study locations

5 sites
  • Anaheim Clinical Trials LLC /ID# 250098
    Anaheim, California 92801-2658, United States
  • Clinical Pharmacology of Miami /ID# 250099
    Miami, Florida 33014, United States
  • Acpru /Id# 249681
    Grayslake, Illinois 60030, United States
  • Bio-Kinetic Clinical Applications, LLC /ID# 250181
    Springfield, Missouri 65802, United States
  • PPD Clinical Research Unit - Austin /ID# 250672
    Austin, Texas 78744, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2022 to primary completion in Apr 2023, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2022
First posted
Oct 5, 2022
StartActual
Sep 28, 2022
Primary completionActual
Apr 20, 2023
CompletionActual
Apr 20, 2023
Last update
Apr 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05567029
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Oct 5, 2022
Start date
Sep 28, 2022
Primary completion
Apr 20, 2023
Completion
Apr 20, 2023
Last update
Apr 28, 2023

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion